Dysglycemia and fluoroquinolones: Are you putting patients at risk?

Journal of Family Practice

Volumn 56, Issue 2, 2007, Pages 101-107

  Catero, Martin ^a,b  

^a HonorHealth Research Institute   (United States)

^b Heuser Family Medicine Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEPHALOSPORIN; CIPROFLOXACIN; FLUOROPYRIMIDINE DERIVATIVE; GATIFLOXACIN; GLIBENCLAMIDE; GLIMEPIRIDE; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; PIOGLITAZONE; REPAGLINIDE; SULFONYLUREA;

ABDOMINAL INFECTION; ABDOMINAL PAIN; ACUTE PYELONEPHRITIS; ACUTE SINUSITIS; ANOREXIA; ANTHRAX; BONE INFECTION; COMMUNITY ACQUIRED PNEUMONIA; DIABETES MELLITUS; DIARRHEA; DISORDERS OF CARBOHYDRATE METABOLISM; DIZZINESS; DRUG CONTRAINDICATION; DRUG INDICATION; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; GLUCOSE BLOOD LEVEL; GONORRHEA; HEADACHE; HIGH RISK PATIENT; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INFECTIOUS ARTHRITIS; INFECTIOUS DIARRHEA; KIDNEY FAILURE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTPATIENT; POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; PROSTATITIS; REVIEW; RISK FACTOR; SKIN INFECTION; SOMNOLENCE; TASTE DISORDER; TREATMENT INDICATION; URINARY TRACT INFECTION; VOMITING;

ADOLESCENT; ADULT; AZA COMPOUNDS; BACTERIAL INFECTIONS; BLOOD GLUCOSE; CIPROFLOXACIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG APPROVAL; EVIDENCE-BASED MEDICINE; FAMILY PRACTICE; FEMALE; FLUOROQUINOLONES; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; INCIDENCE; MALE; MIDDLE AGED; OFLOXACIN; QUINOLINES; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 33847137385     PISSN: 00943509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Bristol-Myers Squibb Company. Tequin (gatifloxacin) package insert. Princeton, NJ; 2006.
2. Bayer Pharmaceuticals. Avelox (moxifloxacin) tablets/injection package insert. West Haven, CT: Bayer Pharmaceuticals; 2004.
3. Ortho-McNeil Pharmaceuticals. Levaquin (levofloxacin) tablets/Injection package insert. Raritan, NJ: Ortho-McNeil; 2004.
4. Bayer Corporation. Cipro (ciprofloxacin) package insert. West Haven, CT; 2003.
5. Park-Wyllie LY, Juurlink DL, Kopp A, et al. Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med 2006; 354:1352-1361. Epub 2006 Mar 1.
6. Mohr JF, McKinnon PS, Peymann PJ, et al. A retrospective, comparative evaluation of dysglycemias in hospitalized patients receiving gatifloxacin, levofloxacin, ciprofloxacin, or ceftriaxone. Pharmacother 2005; 25:1303-1309.
7. Akpunow B, Michaelis J, Uy CN, et al. Multicenter postmarketing assessment of levofloxacin in the treatment of adults with community-acquired pneumonia. Clin Infect Dis 2004; 38:S5-S15.
8. Letourneau G, Morrison H, McMorran M. Gatifloxacin (Tequin): hypoglycemia and hyperglycemia. Can Adverse React Newsletter 2003; 13:1-2.
9. Frothingham R. Gatifloxacin associated with a 56-fold higher rate of glucose homeostasis abnormalities than comparator quinolones in the FDA spontaneous reporting database. Presented at the 44th interscience conference on antimicrobial agents and chemotherapy. Washington, DC, October 3-November 2, 2004.
10. Smith KM, Lomaestro BM. What role do fluoroquinolone antimicrobial agents play in cardiac dysfunction and altered glycemic control? J Pharm Pract 2003; 16:349-360.
11. Donaldson AR, Vandiver JF, Finch, CK. Possible gatifloxacin-induced hyperglycemia. Ann Pharmacother 2004; 38:602-605.
12. Saraga A, Yokokura M, Gonoi T, et al. Effects of fluoroquinolones on insulin secretion and β-cell ATP-sensitive K+ channels. Eur J Pharm 2004; 497: 111-117.
13. LeBlanc M, Belanger C, Cossette P. Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy. Pharmacother 2004; 24:926-931.
14. Menzies DJ, Dorsainvil PA, Cunha BA, et al. Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents. Am J Med 2002; 113:232-234.
15. Lin G, Hays DR Spillane L. Refractory hypoglycemia from ciprofloxacin and glyburide interaction. J Toxicol Clin Toxicol 2004; 42:295-297.
16. Graumlich JF, Habis S, Avelino RR, et al. Hypoglycemia in inpatients after gatifloxacin or levofloxacin therapy: nested case control study. Pharmacother 2005; 25:1296-1302.
17. Gajjar DA, LaCreta FP, Kollia GD, et al. Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with non-insulin-dependent diabetes mellitus maintained with diet and exercise. Pharmacother 2000; 20:76S-86S.
18. Gajjar DA, LaCreta FP, Uderman HD, et al. A dose-escalation study of the safety, tolerability, and pharmacokinetics of intravenous gatifloxacin in healthy adult men. Pharmacother 2000; 20:49S-58S.
19. Gavin JR, Kubin R, Choudri S, et al. Moxifloxacin and glucose homeostasis. Drug Saf 2004; 27:671-686.
20. Pichichero ME, Arguelas A, Dagan R. Safety and efficacy of gatifloxacin therapy for children with recurrent acute otitis media (AOM) and/or AOM treatment failure. Clin Infect Dis 2005; 41:470-478.
21. Lawrence KR, Adra M, Keir C. Hypoglycemia-induced anoxic brain injury possibly associated with levofloxacin. J Infect 2006; 52:e177-180. Epub 2005 Nov 2.
22. Ambrose PG, Bhavnani SM, Cirincione BB, et al. Gatifloxacin and the elderly: pharmacokinetic-pharmacodynamic rationale for a potential age-related dose reduction. J Antimicrob Chemother 2003; S2:434-440.
23. Coblio, NA, Mowrey K, McCright R et al. Use of a data warehouse to examine the effect of fluoroquinolones on glucose metabolism. Am J Health Syst Pharm 2004; 61:2545-2548.
24. Gaglia JL, Wyckoff J, Abrahamson MJ. Acute hyperglycemic crisis in the elderly. Med Clin North Am 2004; 88:1063-1084, xii.